First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ian W FlinnJohn M Burke

Abstract

The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma. This publication provides long-term follow-up data. Patients were monitored for a minimum of 5 years after completion of study treatment for the time-to-event end points of progression-free survival (PFS), event-free survival, duration of response, and overall survival per investigator assessment. Data on the number of patients who received second-line anticancer treatment and the occurrence of other malignancies were also collected. The medians were not reached for any of the time-to event end points for either the BR or R-CHOP/R-CVP study treatment groups by study completion. PFS rates at 5 years were 65.5% in the BR treatment group and 55.8% in the R-CHOP/R-CVP group. The difference in PFS was considered significant with a hazard ratio of 0.61 (95% CI, 0.45 to 0.85; P = .0025). The hazard ratio for event-free survival and durati...Continue Reading

References

Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gaël RouéDolors Colomer
Dec 17, 2014·Blood·Carla CasuloJonathan W Friedberg
Mar 16, 2017·Best Practice & Research. Clinical Haematology·Carla Casulo, Jonathan Friedberg

❮ Previous
Next ❯

Citations

Jul 5, 2019·European Journal of Haematology·Reyad Dada
Aug 2, 2019·Acta Oncologica·Marc SorigueOuti Kuittinen
Jun 28, 2019·Current Opinion in Oncology·Dominique BronUNKNOWN Eurobloodnet for rare diseases and EHA SWG ‘Aging and Hematology’
Jan 31, 2020·British Journal of Haematology·Tarec Christoffer El-Galaly, Chan Yoon Cheah
Dec 10, 2019·American Journal of Hematology·Arnold Freedman, Eric Jacobsen
Feb 23, 2020·The Annals of Pharmacotherapy·Michael J BuegeKathryn T Maples
Aug 30, 2020·Cancer Medicine·Ahmad S HalwaniBrian C Sauer
Sep 13, 2020·American Journal of Hematology·Peter BarthAdam J Olszewski
May 10, 2020·HemaSphere·Kai HübelAjay K Gopal
Aug 1, 2020·The Cancer Journal·Simon Rule, Sophie Johns
Dec 14, 2019·Nature Reviews. Disease Primers·Antonino CarboneJude Fitzgibbon
Jan 1, 2020·Hematological Oncology·John ApostolidisHani Al Hashmi
Aug 1, 2020·Annals of Hematology·M PouyiourouUNKNOWN East German Study Group for Hematology and Oncology (OSHO)
Dec 5, 2020·Hematology·Alessandro Broccoli, Pier Luigi Zinzani
Jan 15, 2021·Blood Cancer Journal·Manette A W DinnessenAvinash G Dinmohamed
Feb 11, 2021·Expert Opinion on Biological Therapy·Agrima Mian, Brian T Hill
Jan 12, 2021·Journal of Geriatric Oncology·Jessalyn A WeaverVicki A Morrison
Jan 8, 2021·Journal of Hematology & Oncology·Melissa LumishErel Joffe
Feb 23, 2021·Drugs·Michael Northend, William Townsend
Aug 31, 2020·Hematology/oncology Clinics of North America·Daniel Guy, Brad S Kahl
Aug 31, 2020·Hematology/oncology Clinics of North America·Jia Ruan
Jun 27, 2020·Hematology/oncology Clinics of North America·Ciara L Freeman, Laurie H Sehn
Mar 31, 2021·British Journal of Haematology·Elisabeth SilkenstedtMartin Dreyling
Apr 4, 2021·Journal of Personalized Medicine·Irene DogliottiFederica Cavallo
Apr 4, 2021·International Journal of Environmental Research and Public Health·Chunyang LiAhmad S Halwani
Jun 27, 2020·Hematology/oncology Clinics of North America·Camille Golfier, Gilles Salles
May 5, 2021·Hematological Oncology·Wolfgang KnaufUNKNOWN TLN-Group (Tumour Registry Lymphatic Neoplasms)
Jun 10, 2021·Hematological Oncology·Brad Kahl
Jul 2, 2021·Journal of Clinical and Experimental Hematopathology : JCEH·Kazunori OhnishiMichinori Ogura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.